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Abstract 
Background and Purpose: The humoral immune response in cancer patients can be used for early 
detection of the disease. Autoantibodies raised against tumor-associated antigens (TAAs) are promising 
clinical biomarkers for reliable cancer diagnosis, prognosis, and therapy monitoring. In this study, an 
electrochemical disposable multiplexed immunosensing platform able to integrate difficult- and 
easy-to-express colorectal cancer (CRC) TAAs is reported for the sensitive determination of eight 
CRC-specific autoantibodies. 
Methods: The electrochemical immunosensing approach involves the use of magnetic microcarriers 
(MBs) as solid supports modified with covalently immobilized HaloTag fusion proteins for the selective 
capture of specific autoantibodies. After magnetic capture of the modified MBs onto screen-printed 
carbon working electrodes, the amperometric responses measured using the hydroquinone (HQ)/H2O2 
system were related to the levels of autoantibodies in plasma. 
Results: The biosensing platform was applied to the analysis of autoantibodies against 8 TAAs described 
for the first time in this work in plasma samples from healthy asymptomatic individuals (n=3), and patients 
with high-risk of developing CRC (n=3), and from patients already diagnosed with colorectal (n=3), lung 
(n=2) or breast (n=2) cancer. The developed bioplatform demonstrated an improved discrimination 
between CRC patients and controls (asymptomatic healthy individuals and breast and lung cancer 
patients) compared to an ELISA-like luminescence test. 
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Conclusions: The proposed methodology uses a just-in-time produced protein in a simpler protocol, 
with low sample volume, and involves cost-effective instrumentation, which could be used in a 
high-throughput manner for reliable population screening to facilitate the detection of early CRC patients 
at affordable cost. 
Key words: colorectal cancer; biosensor; early cancer detection; electrochemical bioplatforms; halotag fusion 
proteins; liquid biopsy 
Introduction 
Colorectal cancer (CRC) is the second deadliest 
cancer worldwide because of its late diagnosis. The 
5-year survival rate associated to late diagnosis drops 
to 6-10% [1]. The study of the humoral immune 
response has been demonstrated useful to identify 
tumor-associated antigens (TAAs) in CRC with 
diagnostic ability. Autoantibodies against TAAs 
appear up to three years before clinical symptoms 
because of the immune system amplification, making 
them interesting targets for early cancer detection 
[2-6]. Early CRC diagnosis by population screening 
would increase overall patient well-being, as well as 
have an important impact on overall Health Systems 
since 90% of early diagnosed patients are successfully 
cured. 
By protein and phage microarrays, among other 
approaches, numerous CRC TAAs whose 
autoantibodies have potential diagnostic ability have 
been described [4, 7-12]. However, the detection of 
autoantibodies to some of these TAAs had to be 
discarded because they were difficult-to-express 
and/or purify proteins because of degradation or 
aggregation during purification or storage. These 
problems make it very difficult and time-costly (if 
possible) to include them into multiplexed diagnostic 
panels. Thus, the development of multiplexed 
biosensing strategies coupled to in vitro expression 
systems for autoantibody detection able to overcome 
such problems would be of great interest. On the one 
hand, mammalian cellular extracts would be ideal 
since it would allow the proteins to be expressed in a 
short period of time with correct folding and no 
degradation to ensure its functionality. On the other 
hand, current electrochemical biosensing platforms, 
entailing straightforward processes and capable of 
accurately detecting specific targets in scarcely treated 
biofluids represent an interesting alternative to 
conventional immunoassays. Their versatility, 
amenability to detect numerous molecular targets 
simultaneously with high levels of sensitivity and 
specificity, capacity for automation, affordability, 
portability and minuscule amount of sample 
requirement make them ideal candidates to be 
adapted in clinical routine for point-of-care (POC) 
diagnosis of cancer and other prevalent diseases 
[13-28].  
This work reports the construction of an 
electrochemical immunosensing platform using in 
vitro transcription/translation expressed HaloTag 
fusion proteins self-assembled onto commercial 
magnetic microparticles (MBs). HaloTag is an 
engineered dehalogenase developed to covalently 
bind to halogenated alkanes [29, 30], which in 
addition can improve the solubility of fusion proteins 
providing higher yields, purity and overall recovery 
of the expressed proteins in comparison to other tags 
as FLAG, 3×FLAG or His(6)Tag [30]. Amperometric 
detection at screen-printed carbon electrodes (SPCEs) 
was performed to evaluate the diagnostic potential of 
a novel autoantibody panel composed of eight TAAs 
(GTF2B, MAPKAPK3, PIM1, PKN1, SRC, STK4, 
SULF1, and p53) previously validated or not 
validated for CRC diagnosis because of their difficulty 
to be expressed or purified [7, 9]. It is worth to remark 
that in a previous work, we reported the use of MBs 
coupled to in situ expressed HaloTag fusion proteins 
and electrochemical detection at SPCEs for the 
accurate determination of blood autoantibodies. 
However, this technology was applied only to the 
determination of antibodies against a single TAA 
(p53) [13]. This work showed that the HaloTag fusion 
protein-based electrochemical immunosensing was 
less prone to false results than ELISA involving 
recombinant TAAs produced in bacterial hosts. This 
fact was attributed to the differences in concentration, 
type, and immobilization of bioreceptors (p53 
expressed in bacteria vs HaloTag-p53 expressed in a 
mammalian milieu) which certainly affected the 
autoantibody capture efficiency, and to the 
remarkably higher sensitivity (440 times) and the 
larger sera dilution factor required by the 
electrochemical method compared to the ELISA test. 
Interestingly, the analysis of the difficult-to-express 
TAAs PKN1, SRC, and SULF1 could not be carried 
out by ELISA and/or Luminex methods. Moreover, 
PIM1 forms dimers that can block antibody 
recognition sites and, therefore, if aggregation occurs 
becomes useless for patient diagnosis, as in 
Luminex-based approaches [7]. In addition, 
MAPKAPK3, STK4, and p53 were included as 
controls to evaluate whether these TAAs maintain 
their previously described diagnostic potential [7, 9]. 
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In vitro expressed TAAs coupled to HaloTag were 
immobilized in situ into MBs to avoid protein 
degradation. Then, modified MBs were incubated 
with plasma samples from controls, CRC patients, or 
colorectal individuals carrying premalignant lesions 
to assess the diagnostic ability of the autoantibodies. 
The developed biosensing multiplexed platform can 
be envisioned as a point-of-care (POC) device capable 
of detecting these autoantibodies in plasma.  
Results 
Colorectal cancer tumor-associated antigens 
selection  
Previous studies related to the analysis of the 
humoral immune response in CRC identified 91 
possible TAAs by using protein microarrays. Among 
them, difficult-to-express and difficult-to-purify 
TAAs or autoantigens suffering from extensive 
degradation with high diagnostic potential were 
discarded for analysis and/or validation. Therefore, 
only a panel consisting of 6 TAAs was considered for 
early CRC detection [4, 7, 10, 11].  
In this work, we have developed an 
electrochemical immunosensing strategy based on 
HaloTag technology able to include previously 
discarded proteins, due to their challenging 
production and/or purification, into diagnostic 
panels with the ultimate goal of constructing a POC 
device able to discriminate CRC patients and 
individuals carrying premalignant lesions from 
controls. For such a purpose, eight CRC TAAs were 
selected for the study: GTF2B, MAPKAPK3, PIM1, 
PKN1, SRC, STK4, SULF1, and p53, where PIM1, 
PKN1, SRC, and SULF1 (and p53) are 
difficult-to-express and/or purify proteins and 
GTF2B, MAPKAPK3, and STK4 are easy-to-express 
proteins used as controls to ascertain whether this 
approach maintains their previously described CRC 
diagnostic ability [7, 9]. 
CRC TAAs encoding cDNAs were cloned as 
HaloTag-fusion proteins into vectors optimized for in 
vitro protein expression for subsequent covalent 
immobilization of the proteins onto MBs for direct 
evaluation of autoantibody levels in plasma of 
patients and controls (Table 1 and Table S1) to avoid 
any degradation or precipitation during purification 
and storage, compulsory steps for other techniques 
(i.e. ELISA, Luminex…) [13]. Once verified the correct 
protein expression and established the diagnostic 
signature by luminescence [31], a multiplexed 
electrochemical immunoassay capable of detecting 
autoantibody presence as a POC device for CRC 
detection was developed (Figure 1). 
Cloning and in vitro protein expression 
To evaluate whether the proposed system of in 
vitro protein expression and immobilization of the 
autoantibody targets onto MBs could successfully 
render all TAA fusion proteins, we evaluated their 
correct in vitro expression. Figure S1A shows as 
immunostaining of the expression product exhibited a 
correct expression. Next, to verify that the HaloTag 
fusion proteins were functional for their covalent 
binding to functionalized chloroalkane MBs, and thus, 
could be used for selective capture of autoantibodies 
against them, we immobilized them onto MBs 
through the HaloTag and incubated the resulting 
HaloTag fusion protein-MBs with, alternatively, a 
specific antibody against the tag or against the 
indicated TAAs. A specific luminescence signal was 
obtained for all proteins using the anti-HaloTag mAb 
(Figure S1B) or for the indicated TAAs using their 
specific antibodies (Figure S1C). These results 
confirmed the successful immobilization of functional 
HaloTag fusion proteins on the MBs and the great 
potential of the protocols applied to any protein 
without particular optimization.  
 
Table 1. Samples used in the study. 
Classification Age (years) 
± SD 
Sample size 
(Male/Female) 
Control Negative 
colonoscopy/asymptomatic 
44±7 11/19 
Other cancers 58±12 16/24 
Pathological Premalignant 60±7 16/9 
CRC 70±11 13/13 
 
Evaluation of autoantibody seroreactivity 
levels by luminescence beads immunoassay 
Once established the optimal working 
conditions, we evaluated the optimal plasma dilution 
to be used by luminescence beads immunoassay to 
compare the results with those previously reported 
for GTF2B, MAPKAPK3, and STK4 [7, 9]. Figure S1D 
shows as better discrimination between the tumor and 
control group for the determination of autoantibodies 
a 1:300 dilution. Next, we proceeded to evaluate the 
seroreactivity levels of 125 individuals -31 
asymptomatic healthy individuals, 20 lung cancer 
patients, 20 breast cancer patients, 28 premalignant 
individuals, and 26 CRC patients- to determine 
whether autoantibody presence could discriminate 
between groups, and to assess whether the developed 
methodology was successful to be used with 
difficult-to-express and easy-to-express CRC TAAs 
proteins for diagnostic purposes (Figure 2).  
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Figure 1. Schematic design of the strategy. Autoantibody targets were identified using protein microarrays incubated with plasma samples from CRC patients. Targets 
were then in vitro expressed as HaloTag fusion proteins for their subsequent immobilization onto MBs for evaluation of their diagnostic potential and development of a 
multiplexed electrochemical immunosensing platform for CRC early diagnosis. 
 
Overall, we found that the evaluated 
autoantigens target of autoantibodies -except p53- 
could discriminate with statistical significance 
(p<0.05) among the pathological individuals (CRC 
patients and premalignant individuals) and all control 
groups, as well as all controls vs CRC patients (Figure 
3A, B). However, when comparing the control and 
premalignant patients, GTF2B and p53 failed to 
distinguish between groups with statistical 
significance even though the premalignant group 
showed higher autoantibody levels (Figure 3C). When 
comparing the autoantibody levels in asymptomatic 
individuals and the pathological group, all the 
autoantibody targets except SRC could significantly 
discriminate between groups, while all autoantibody 
targets could discriminate between them with 
statistical significance when comparing the 
asymptomatic individuals with the CRC patients 
(Figure 3D, E). However, GTF2B, SRC, SULF1 and p53 
could not discriminate between the asymptomatic 
and premalignant subjects with statistical significance 
although the premalignant group showed higher 
autoantibody levels (Figure 3F). To evaluate whether 
autoantibodies were CRC specific, we compared 
levels between the asymptomatic subjects and breast 
and lung cancer individuals. Autoantibodies against 
p53 could discriminate with statistical significance 
(p<0.05) between both groups but none of the CRC 
TAAs (Figure 3G).  
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Figure 2. Autoantibody measurement by luminescence of the plasma samples. Evaluation of autoantibody presence showed that the luminescence signal obtained for 
the premalignant and CRC groups was considerably higher than the signal obtained for the control groups.  
 
Figure 3. Statistical analysis of autoantibody levels according to patients’ groups. Autoantibodies against the eight targets could discriminate between the control and 
pathological group (A) and between controls and CRC patients (B). However, GTF2B and p53 could not discriminate between the control and premalignant subjects (C). All the 
autoantibodies but SRC could discriminate between the asymptomatic subjects and the pathological group (D). Moreover, the 8 autoantibodies could discriminate between the 
asymptomatic individuals and CRC patients (E). However, only MAPKAPK3, PIM1, PKN1, and STK4 could discriminate between asymptomatic and premalignant subjects (F). 
Furthermore, just p53 could differentiate between the asymptomatic individuals and breast and lung cancer patients (G). EBNA-I seroreactivity was analyzed as a test for the 
specificity of the assay, showing similar levels in all groups (H). Since >95% of the human population has been infected with the Epstein Barr virus, antibodies specific against 
EBNA1 would serve as specific control of the seroreactivity among all the analyzed groups. All controls: asymptomatic individuals, and breast and lung cancer patients. 
 
EBNA1 seroreactivity was analyzed as control of 
the specific CRC seroreactivity. A no clear pattern of 
seroreactivity to EBNA1 was observed among all 
groups with non-significant p-values. These results 
clearly confirmed that the seroreactivity observed for 
the indicated CRC-specific autoantibodies was 
characteristic of the analyzed groups (Figure 3H). 
Evaluation of the diagnostic potential of 
selected autoantibodies  
Next, ROC curves were obtained to search for 
the optimal TAA combination to discriminate 
between patients and controls (Table S2). The optimal 
AUC values were achieved with those autoantibodies 
that could discriminate patients with statistical 
significance, with a value of 92.4% (sensitivity 76.0%, 
specificity 96.7%) when comparing the asymptomatic 
group vs the CRC patients, and 91.8% (sensitivity 
76.0% and specificity 98.6%) when factoring in the 
breast and lung cancer subjects with the 
asymptomatic group against the CRC subjects (Figure 
4A, B).  
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Figure 4. Diagnostic potential of the simultaneous detection of the TAAs. The diagnostic potential was analyzed by ROC curves comparing the asymptomatic vs CRC 
group (A), all controls vs CRC subjects (B), asymptomatic individuals vs premalignant subjects (C), and all controls vs the premalignant group (D). All controls: asymptomatic 
individuals, and breast and lung cancer patients. 
 
To evaluate whether the proposed markers 
could also detect premalignant subjects, ROC curves 
comparing the asymptomatic group with the 
premalignant subjects as well as the control group 
(with the breast and lung cancer subjects) with the 
premalignant subjects were constructed. AUC values 
of 78.4% (sensitivity 72%, specificity 80%) and 83.0% 
(sensitivity 84%, specificity 75.7%) were found, 
respectively (Figure 4C, D). These AUC values, 
although lower than those obtained for discriminating 
the CRC subjects, also indicated that the markers are 
useful for the early detection of premalignant 
individuals. 
These data were compared with those 
previously reported for GTF2B, STK4, MAPKAPK3, 
and p53 to ascertain whether this approach keeps 
their previously reported CRC diagnostic values 
(Table S2, and Table S3). Our data showed that the 
here proposed approach is suitable for 
difficult-to-express and difficult-to-purify TAAs as 
well as for those easy-to-produce. In this sense, 
GTF2B, STK4, MAPKAPK3 and p53 showed a similar 
or even higher diagnostic ability using the here 
described approach than that previously reported 
(Table S3), which may be attributed to the lower false 
positives and the high sensitivity demonstrated by the 
HaloTag technology compared to ELISA [4, 7, 9, 11, 
13]. 
Development of an electrochemical 
multiplexed immunosensing platform as a tool 
for early and affordable diagnostic test 
The CRC autoantibody targets were also tested 
by means of a multiplexing electrochemical 
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immunosensing platform as a proof-of-concept of a 
POC device that could be used in a clinical setting for 
CRC detection (Figure 5A).  
Under the optimized conditions described in the 
Experimental Section, the ability of the developed 
platform to detect the presence of autoantibodies 
against GTF2B, MAPKAPK3, PIM1, PKN1, SRC, 
STK4, SULF1, and p53 in human plasma was tested. 
Three asymptomatic plasma samples, samples from 
three premalignant individuals, three CRC patients 
and four breast and lung cancer patients were 
analysed (Figure 5B, C). As it was previously 
observed by luminescence, most CRC patients were 
reactive to most if not all TAAs, while premalignant 
individuals were reactive to >4 TAAs apart from p53. 
We analyzed premalignant individuals, CRC 
patients and control groups according to this 
differential specific seroreactivity as cut-off. 
Remarkably, none of the asymptomatic patients (with 
most values close to background) and breast cancer 
patients showed seroreactivity to four or more 
different CRC autoantigens and were clearly 
discriminated from CRC patients. However, one lung 
cancer patient also presented seroreactivity to 4 out of 
8 different CRC autoantigens. In addition, all 
premalignant and CRC individuals possessed 
autoantibodies for more than four CRC autoantigens 
and showed a clear signal above background, 
indicating the usefulness of the methodology as a 
possible clinical tool for the detection of CRC (Figure 
5D). Furthermore, ROC curve analysis showed that 
the multiplexed simultaneous detection of 
autoantibodies against the eight CRC TAAs has a 
powerful diagnostic ability for CRC and colorectal 
premalignant individuals, with an AUC of 100% 
(Figure 5E). 
Collectively, these results show that the 
developed methodology overcomes the drawbacks 
regarding purification, degradation and 
immobilization of difficult-to-express CRC TAAs so 
that they do not have to be discarded with the 
implicated loss of diagnostic ability. Moreover, the 
use of these TAAs allowed us to find a novel 
diagnostic signature with high potential for the 
detection of CRC through a POC device. 
Discussion 
The humoral immune response has been proven 
useful for early cancer diagnosis [2, 3, 5, 32-34]. 
Through different methodologies, such as ELISA, 
SEREX, SERPA, or other proteomic techniques, 
multiple potential tumor associated targets of the 
immune system have been identified [8, 11, 12, 35-37]. 
However, these methodologies are not ideal for 
validation or to be used in a clinical setting, since they 
require either large volumes of biological samples or 
are expensive and time-consuming when they have to 
detect multiple targets simultaneously, or require a 
high specialized setting. In this work, we have 
optimized a novel methodology based on the in vitro 
expression of CRC-specific autoantibody targets 
coupled to HaloTag that allows their immobilization 
onto MBs and the construction of an electrochemical 
immunosensing platform with multiplexing 
capabilities ideal as a POC device for the analysis in 
serum/plasma. 
In vitro protein expression using mammalian 
cellular extracts offers numerous advantages versus 
the most common bacteria and yeast expression 
systems. As it has been shown in previous studies, 
some TAAs in CRC exhibited expression and 
purification drawbacks which made it hard to 
develop with them a methodology for CRC diagnosis 
[4, 7, 9-11]. The expression of the autoantibody targets 
coupled to the HaloTag using a previously developed 
system for p53 made it possible to obtain the 
difficult-to-express proteins previously discarded 
with their correct folding and no degradation, and in 
less time than with conventional techniques. 
Moreover, through the HaloTag, these functionalized 
proteins were covalently immobilized in situ to carry 
out the assay, so that no storage or dimerization 
problems occurred and autoantibody detection was 
not hindered by their degradation or oligomerization. 
It is important to note also that this protocol for in situ 
production and selective capture of the HaloTag 
fusion proteins onto the MBs is much simpler and 
shorter (just one overnight step) than the conventional 
procedure to get purified TAAs produced in bacteria, 
insect, or mammalian cells, which usually requires 
weeks or months, and sometimes makes it impossible 
to produce difficult-to-express or -purify proteins and 
are more prone to give false positive results due to the 
presence of bacterial contaminants.  
Autoantibody detection in plasma samples is an 
interesting alternative to conventional diagnostic 
techniques for CRC -such as colonoscopy- since it is a 
non-invasive (or low- invasive since blood collection 
is required) approach that can detect the disease at 
either premalignant (low- and high-grade adenomas) 
and CRC at early stages when its treatment get more 
than 90% of curation only with tumor resection. Up to 
date, autoantibody levels have been described to be 
useful for the diagnosis of multiple different diseases 
[35, 38-40], apart from other cancer malignancies [41, 
42], and thus, this methodology could also be applied 
for different diseases. 
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Figure 5. Autoantibody measurement in plasma samples by the multiplexed electrochemical immunosensing platform. (A) Schematic design of the proposed 
strategy. (B, C) Amperometric responses obtained for the TAAs were larger for the premalignant and CRC subjects in comparison to the asymptomatic, where they were 
almost undetectable. (D) Percentage of patients positive to CRC related autoantibodies detected by the biosensor. (E) ROC curve of autoantibody detection against all targets 
using the electrochemical immunosensing platform. Premalignant, premalignant colorectal individuals. 
 
In this work, we found that the simultaneous 
detection of autoantibodies against GTF2B, 
MAPKAPK3, p53, PIM1, PKN1, SRC, STK4, and 
SULF1 could discriminate between control 
individuals and CRC patients and premalignant 
subjects with an AUC well above than that for CEA 
(the established clinical marker recommended for 
monitoring recurrent CRC) 90% vs 80%, and 
Theranostics 2020, Vol. 10, Issue 7 
 
 
http://www.thno.org 
3030 
especially for the comparison between control 
individuals and premalignant patients 91% vs 57%. 
Moreover, this autoantibody panel was specific of 
CRC, since it could not discriminate individuals with 
breast and lung cancer patients, indicating their great 
potential in a clinical setting. 
Electrochemical biosensors are attractive 
potential diagnostic tools, since they offer numerous 
advantages in comparison to other techniques such as 
ELISA or Luminex [13, 43, 44]. They have a great 
multiplexing capability, with ability to detect different 
biomarkers in nature in a single measurement and 
directly in complex biological matrices [43]. This 
characteristic makes this type of biosensors ideal for 
CRC diagnosis since it would allow for the 
simultaneous autoantibody detection against the 
eight TAAs using a minimal plasma sample volume. 
The multiple detection of autoantibodies is needed for 
a more specific and sensitive diagnosis of the disease, 
and to discriminate CRC patients from other cancer 
patients. As shown in this work, the ROC curves of 
the biosensing approach demonstrated that this 
methodology could be successfully used in clinics to 
detect CRC patients. In addition, the developed 
methodology meets better the requirements of 
hospital routine and POC testing since it greatly 
reduces assay time and production costs. In 
comparison to other techniques, the simultaneous 
detection of the autoantibody presence takes up to 3.5 
hours after protein immobilization on chloroalkane 
MBs. This assay time is much shorter than that 
required by using ELISA or Luminex for testing the 
same number of TAAs (about 6 hours after protein 
immobilization without considering the overnight 
immobilization of the TAAs by ELISA or the 3 days 
required after protein immobilization by Luminex 
prior to seroreactive analysis). Importantly, the 
multiplexed electrochemical biosensing for 8 TAAs 
detection is about 3 euros per patient that would be 
10-20 times less expensive than other conventional 
immunoassays. In addition, the TAAs used for 
selective capture of the autoantibodies are expressed 
just-in-time using a cell-free expression system, 
allowing for the first time the determination of 
autoantibodies against TAAs difficult to express 
and/or purify. Furthermore, this methodology avoids 
the expensive and time demanding protocols required 
to express and purify cancer recombinant proteins in 
bacterial, insect, or mammalian cells and the concerns 
regarding the stability and integrity of the protein 
during storage, as well as the presence of potentially 
immunogenic bacterial products that can be a source 
of false positives in ELISA or Luminex assays.  
Besides the use of HaloTag technology, the 
proposed electrochemical immunosensing platform 
possesses unique features, in comparison with ELISA, 
derived from the use of MBs as solid supports to 
perform the bioassay and the electrochemical 
transduction at disposable electrodes. MBs have 
demonstrated to be a powerful and versatile tool to 
improve the sensitivity of bioassays, minimize matrix 
effect, reduce largely the assay time and make 
analytical procedures more compatible with higher 
sample throughput and automation [45-49]. 
Screen-printed electrodes (SPEs), can be massively 
and inexpensively produced from a variety of 
materials, in different geometries and in miniaturized 
and multiplexed formats and allow working with 
small sample volumes [47, 50]. Moreover, the 
developed technology is amenable to automate and 
implement using cost-effective and low-power 
requirement instrumentation, which make it 
applicable in both diagnostic and outpatient routines 
and even in limited-resource settings [23]. All these 
interesting features and the ability to discriminate 
between patient groups, make the developed 
bioplatform a promising tool compared both to ELISA 
and the luminescence approach to be readily 
implemented in low-cost, simple use, short time 
analysis and in high-throughput and multiplexed 
devices for early diagnostics, patient follow-up, and 
monitoring of cancer patients through reliable 
autoantibodies signatures determination. However, 
the main issue the developed electrochemical 
methodology would have to face might be precisely to 
convince of the potential and these competitive 
advantages to the users of ELISA technology, very 
accustomed with using this methodology long 
adopted in centralized laboratories for this type of 
determinations. 
In conclusion, in this work we have designed 
and optimized a novel and versatile electrochemical 
biosensing strategy compatible with POC demands 
for the detection of multiple TAAs, even those 
difficult-to-be-expressed, based on the use of HaloTag 
fusions proteins obtained by in vitro expression 
systems maintaining or increasing their diagnostic 
ability. The autoantibodies against the described 
TAAs could discriminate CRC and premalignant 
subjects from control individuals with great 
specificity and sensitivity. The capability of the 
developed technology was demonstrated by 
performing 104 and 1,000 determinations using 
electrochemical and chemiluminescence detection, 
respectively. The results obtained using both 
detection techniques were comparable and showed 
that while no seroreactivity was observed against any 
of the tumor antigens selected in asymptomatic 
patients, 100% of patients with premalignant lesions 
or CRC exhibit seroreactivity to at least 4 out of the 8 
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selected antigens. These results confirm the possibility 
of reliably and minimally invasively diagnose CRC by 
analyzing molecular signatures comprising these 
eight autoantibodies. Although further improvements 
could be made by including other CRC TAAs to 
increase the diagnostic ability of the developed 
electrochemical technology, and further validations 
using larger independent patient’s cohorts, the 
capabilities and advantages demonstrated so far 
reveal its potential to integrate difficult- and 
easy-to-express TAAs to contribute to early and 
reliable CRC diagnosis, and thus greatly increasing 
patient income and benefiting the cost associated to 
CRC treatment by Health Systems.  
Materials and methods 
Plasma samples 
The Institutional Ethical Review Boards of the 
Instituto de Salud Carlos III, Hospital Clínico San 
Carlos, and La Paz Hospital approved this study on 
biomarker discovery and validation (CEI PI 45). 
Plasma samples (Table 1 and Table S1) were used 
accomplishing all the ethical issues and relevant 
guidelines and regulations.  
Plasma samples (Table 1 and Table S1) were 
obtained from the biobanks of the Hospital Clínico 
San Carlos and Hospital La Paz after approval of the 
Ethical Review Boards of these institutions. Breast and 
lung cancer samples provided by Hospital 
Universitari de Sant Joan (Tarragona, Spain) were 
used accomplishing all the ethical issues and relevant 
guidelines and regulations. All subjects in the study 
gave their written informed consent to participate and 
all experiments were performed in accordance with 
relevant guidelines and regulations. 
For the analysis of the CRC diagnostic ability of 
autoantibodies, a panel of 125 plasma samples from 
colorectal cancer patients and premalignant colon 
subjects (low- and high-grade adenomas), and control 
individuals (asymptomatic healthy and negative 
colonoscopy individuals, Fecal Occult Blood Test –
FOBT- positive and colonoscopy negative individuals, 
and breast and lung cancer patients) was used (Table 
1, and Table S1). Plasma samples were collected using 
a standardized sample collection protocol and stored 
at −80°C until use [4, 9-11]. 
Gateway plasmid construction, gene cloning, 
DNA preparation and protein expression 
Sequence-verified, full-length cDNA plasmids 
containing selected targets for validation in flexible 
pDONR221 or pENTR223 vector system were 
obtained from the publicly available DNASU Plasmid 
Repository (https://dnasu.org/DNASU/) [51]. The 
ORFs were transferred by LR clonase reactions 
(Invitrogen, Carlsbad, CA), alternatively, to a 
pANT7_cHalo or pJFT7_nHalo vector for in vitro 
protein expression to get the autoantigens expressed 
as fusion proteins to HaloTag in the C-terminal or in 
the N-terminal, respectively [13, 52]. All donor and 
expression plasmids were sequence verified prior to a 
subsequent use.  
To obtain high-quality supercoiled DNA, 
plasmids were transformed into TOP10 E. coli cells 
and grown in 250 mL Luria Bertani (LB) 
supplemented with the appropriate antibiotic 
(100 μg/mL Ampicilin and 40 μg/mL kanamycin). 
Plasmid DNA was purified using the NucleoBond 
Xtra Midi kit (Macherey-Nagel Inc., Bethlehem, PA). 
Proteins were cell-free expressed in vitro using HeLa 
cell lysate from the 1-Step Human Coupled IVT Kit 
(Thermo Fisher Scientific, Waltham, MA) per 
manufacturer's recommendations to carry out the 
ELISA studies. 
SDS-PAGE and western blot analysis  
SDS-PAGE and western blot analysis to assess 
protein quality was performed as previously reported 
[53]. Briefly, 0.67 µL of the in vitro protein extracts 
were run in 10% SDS-PAGE and transferred to 
nitrocellulose membranes (Hybond-C extra). After 
blocking, membranes were incubated overnight at 
4 °C with an anti-HaloTag monoclonal antibody. 
Immunodetection on the membranes was achieved 
using HRP-conjugated goat anti-mouse IgG antibody 
(Table S4). Chemiluminescence signal was developed 
with ECL Western Blotting Substrate (Thermo 
Scientific) and detected on an Amersham Imager 680 
(GE Healthcare).  
EBNA-1 ELISA  
Colorimetric ELISA for EBNA-I antibody 
determination for the evaluation of the CRC 
autoantibody response specificity was accomplished 
by coating 0.05 µg of EBNA-I protein kindly provided 
by Protein Alternatives, S.L. per well in 50 µL of 
phosphate-buffer saline solution (PBS) in 96-well 
Maxisorp plates (Nunc) overnight at 4 ºC. Plates were 
then blocked using a 3% (w/v) skimmed-milk 
solution in PBS supplemented with 0.1% Tween 
(PBST) for 1 h at 37 ºC and then incubated 1 h at 37ºC 
with 50 µL of the 1:300 diluted plasma samples. After 
extensive washing with PBST, plates were incubated 
for 1 h at 37 ºC with 50 µL of an HRP-labeled 
secondary antibody. Colorimetric signal was 
developed as previously described [54, 55]. 
Autoantibody analysis by luminescence beads 
immunoassay 
Protein coupling to Magne HaloTag beads (MBs, 
Promega) was performed overnight at 4 ºC and 
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1000 rpm according to the manufacturer instructions 
using 0.67 µL of IVT expression reaction and 0.5 µL of 
HaloTag MBs per measurement. For covalent binding, 
a mixture of the required amount of protein and MBs 
was made taking into account the number of 
replicates and measurements to be performed [13, 35, 
56]. After extensive washing with PBS, Tween 0.1%, 
Triton X-100 0.05% using a magnet and removal of 
non-covalently bound proteins with 0.1 M glycine, 
pH 2.7, HaloTag fusion proteins immobilized onto 
MBs were blocked with Superblock (Pierce) for 1 h. To 
verify covalent protein immobilization, the HaloTag 
fusion proteins were detected with either 
anti-HaloTag (Promega), or specific antibodies 
against the TAAs followed by 1 h incubation with the 
corresponding diluted HRP conjugated secondary 
antibody (Table S4). Alternatively, they were 
incubated overnight with pooled or individual 
plasma samples at indicated dilutions at 1000 rpm 
and 4 ºC. After washing with PBS, Tween 0.1%, Triton 
X-100 0.05% as above, HRP-conjugated anti-human 
IgG antibody (Dako) 1:10000 diluted in PBS 
supplemented with Tween 20 0.1% (v/v) and 3% 
(w/v) BSA was incubated with the MBs. The MBs 
were collected and placed on black Maxisorp 96-well 
plates (Nunc). Signal was developed using 50 μL of 
SuperSignal ELISA Femto Maximum Sensitivity 
Substrate (Pierce, Rockford, IL) for the detection of 
luminescence on The Spark multimode microplate 
reader (Tecan Trading AG, Switzerland). 
Alternatively, plates were also recorded on an 
Amersham Imager 680 (GE Healthcare). 
Autoantibody analysis by electrochemical 
beads immunoassay 
The protocol was previously reported and 
optimized for the determination of p53 autoantibodies 
[13]. The same protocol was followed for the 
determination of CRC-specific autoantibodies against 
GTF2B, MAPKAPK3, PIM1, PKN1, SRC, STK4, 
SULF1, and p53. To verify the correct protein 
immobilization, the HaloTag fusion proteins were 
detected with anti-HaloTag mAb (Promega), followed 
by 1 h incubation with 1:3000 diluted HRP-conjugated 
anti-mouse IgG (Sigma Aldrich). The amperometric 
measurements were performed in the presence of the 
hydroquinone (HQ)/H2O2 system [57] at disposable 
screen-printed carbon electrodes (SPCEs) upon 
magnetic capture of the MBs bearing the 
immunocomplexes on the working electrode [13]. The 
biorecognition event is monitored by the variation in 
the cathodic current generated by the enzymatic 
(HRP) reduction of H2O2 mediated by HQ and 
measured at −0.20 V (vs a Ag pseudoreference 
electrode) [57]. 
The amperometric measurements were carried 
out with a single SPCE for each measurement (that do 
not take more than 3 min) and discarded afterwards. 
However, no significant change in the working 
protocol would be required to measure simultaneous 
signals at arrays of 8 electrodes or even at 
electrochemical plates of 96 electrodes. 
Statistical analysis 
All statistical analyses were done with Microsoft 
Office Excel and the R program. For the analysis of the 
results obtained by luminescence and electrochemical 
beads immunoassays, Mann-Whitney U test was 
performed, and statistically significant levels were 
considered at p < 0.05. The diagnostic capacity of each 
individual protein as well as the combination of 
markers was evaluated by a receiver operating 
characteristic (ROC) curve. ROC curves, their 
corresponding area under the curve (AUC) and 
maximized sensitivity and specificity values were 
calculated using the R package Epi [58]. 
Supplementary Material  
Supplementary figure and tables. 
http://www.thno.org/v10p3022s1.pdf  
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